SL-164
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H12Cl2N2O |
Molar mass | 319.185 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
SL-164, also known as dicloqualone or DCQ is an analogue of methaqualone developed in the late 1960s by a team at Sumitomo.[1] SL-164 has similar sedative, hypnotic and anticonvulsant properties to the parent compound, but was never marketed for clinical use.[2]
References
- ↑ US 3651230, "Compositions And Methods For Tranquilizing With Substituted 3-Phenyl-4-Quinazolinone Derivatives"
- ↑ Saito C, Sakai S, Yukawa Y, Yamamoto H, Takagi H (December 1969). "Pharmacological studies on 2-methyl-3(2'-methyl-4'-chlorophenyl)-5-chloro-4[H)-quinazolinone (SL-164)". Arzneimittel-Forschung. 19 (12): 1945–9. PMID 4985336.
Alcohols |
|
---|---|
Barbiturates |
|
Benzodiazepines |
|
Carbamates | |
Flavonoids |
|
Imidazoles | |
Kava constituents |
|
Monoureides |
|
Neuroactive steroids |
|
Nonbenzodiazepines | |
Phenols | |
Piperidinediones | |
Pyrazolopyridines | |
Quinazolinones | |
Volatiles/gases |
|
Others/unsorted |
|
See also: Receptor/signaling modulators • GABA receptor modulators • GABA metabolism/transport modulators |
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.